Qrons Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QRON research report →
Price Chart
About the company
Qrons, Inc. is a biotechnology company, which engages in the development of treatments and technologies for neuronal and infectious diseases. Its proprietary patents include Techniques for Promoting Neuronal Recovery, Therapeutic Polypseudorotaxane Hydrogels, and Tellurium Compositions and Techniques for Use Therewith.
- CEO
- Cory J. Rosenberg
- IPO
- 2021
- Employees
- 1
- HQ
- Glendale, BY, US
Get TickerSpark's AI analysis on QRON
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $199.80K
- P/E
- -2.77
- PEG
- -0.02
- P/S
- 0.00
- P/B
- -0.35
- EV/EBITDA
- -4.31
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 5.80%
- ROIC
- 236.10%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-344,000
- Net Income
- $-56,097+92.9%
- EPS
- $-0.00+93.1%
- OCF Growth
- +10.0%
- FCF Growth
- +10.0%
- 52W High
- $0.17
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.06
- Beta
- 0.86
- RSI (14)
- 48
- Avg Volume
- 83
No earnings-call transcripts are available for QRON yet.
- Free Float
- 42.3%
- Shares Outstanding
- 18.00M
- Float Shares
- 7.61M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 22, 22 | Merfeld Ido | other | 325,000 |
| Dec 22, 22 | Meer Jonah | other | 325,000 |
| Dec 22, 21 | Merfeld Ido | other | 325,000 |
| Dec 22, 21 | Meer Jonah | other | 325,000 |
| Dec 10, 20 | Merfeld Ido | other | 325,000 |
| Dec 10, 20 | MEER JONAH | other | 325,000 |
| Dec 17, 19 | Merfeld Ido | other | 325,000 |
| Dec 17, 19 | MEER JONAH | other | 325,000 |
| Jul 1, 19 | BONFIGLIO JOHN N | other | 0 |
| Jul 1, 19 | BONFIGLIO JOHN N | other | 100,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our QRON coverage
Recent articles, reports, and earnings notes.
No research on QRON yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate QRON report →First Person Enters Its Next Phase of Growth Following Early Think Fast™ Momentum
prnewswire.com · Aug 18
Qrons Announces the Addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board to Beef up its Team, as Part of its New Sepsis Research Program
accesswire.com · Nov 20
Qrons Announces Launch of its New Website in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
accesswire.com · Aug 23
Qrons Announces the Filing of a Provisional Patent Application in Furtherance of its Neuronal and Infectious Disease Treatments Development, Including Sepsis
accesswire.com · Aug 14
Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and Traumatic Brain Injuries
accesswire.com · Jul 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.